
4D Molecular Therapeutics, Inc. – NASDAQ:FDMT
4D Molecular Therapeutics stock price today
4D Molecular Therapeutics stock price monthly change
4D Molecular Therapeutics stock price quarterly change
4D Molecular Therapeutics stock price yearly change
4D Molecular Therapeutics key metrics
Market Cap | 272.05M |
Enterprise value | 472.01M |
P/E | -5.08 |
EV/Sales | 250.93 |
EV/EBITDA | -3.04 |
Price/Sales | 270.19 |
Price/Book | 2.19 |
PEG ratio | 0.17 |
EPS | -2.5 |
Revenue | 20.45M |
EBITDA | -116.39M |
Income | -104.55M |
Revenue Q/Q | -90.60% |
Revenue Y/Y | 826.68% |
Profit margin | -8608.08% |
Oper. margin | -8763.96% |
Gross margin | 0% |
EBIT margin | -8763.96% |
EBITDA margin | -569.11% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for free4D Molecular Therapeutics stock price history
4D Molecular Therapeutics stock forecast
4D Molecular Therapeutics financial statements
Jun 2023 | 239K | -29.61M | -12391.63% |
---|---|---|---|
Sep 2023 | 20.20M | -10.25M | -50.76% |
Dec 2023 | -19K | -32.28M | 169910.53% |
Mar 2024 | 28K | -32.40M | -115717.86% |
Mar 2024 | 28K | -32.40M | -115717.86% |
---|---|---|---|
Sep 2025 | 500K | -35.21B | -7043412.06% |
Oct 2025 | 500K | -49.76M | -9952.94% |
Dec 2025 | 500K | -53.21M | -10642.75% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 352503000 | 725.29M | 205.75% |
---|---|---|---|
Sep 2023 | 361613000 | 31.67M | 8.76% |
Dec 2023 | 339891000 | 32.06M | 9.43% |
Mar 2024 | 629884000 | 29.32M | 4.66% |
Jun 2023 | -22.06M | 49.28M | 130.51M |
---|---|---|---|
Sep 2023 | -1.17M | 29.98M | 10.55M |
Dec 2023 | -24.65M | -6.68M | 4.76M |
Mar 2024 | -29.08M | -263.25M | 318.83M |
4D Molecular Therapeutics alternative data
Aug 2023 | 137 |
---|---|
Sep 2023 | 137 |
Oct 2023 | 137 |
Nov 2023 | 137 |
Dec 2023 | 144 |
Jan 2024 | 144 |
Feb 2024 | 144 |
Mar 2024 | 147 |
Apr 2024 | 147 |
May 2024 | 147 |
Jun 2024 | 171 |
Jul 2024 | 171 |
4D Molecular Therapeutics other data
Period | Buy | Sel |
---|---|---|
Jan 2024 | 0 | 614665 |
Feb 2024 | 0 | 104208 |
Mar 2024 | 0 | 7583 |
Apr 2024 | 0 | 9903 |
May 2024 | 0 | 1750 |
Jun 2024 | 0 | 14680 |
Jul 2024 | 0 | 20917 |
Aug 2024 | 0 | 500 |
Sep 2024 | 0 | 500 |
Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement
4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm
4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024
4D Molecular Therapeutics: Some Failures, A Few Key Successes
4D Molecular Therapeutics: Pioneering Gene Therapies And An Impressive Fiscal Performance
4D Molecular Therapeutics: A Complicated Story
4D Molecular Therapeutics: Promising Preliminary Safety And Efficacy For 4D-310
4D Molecular Therapeutics: Another Gene Therapy Player With A Differentiated Profile
Sangamo Therapeutics: Strong Fabry Data Puts Them In The Lead
-
What's the price of 4D Molecular Therapeutics stock today?
One share of 4D Molecular Therapeutics stock can currently be purchased for approximately $6.52.
-
When is 4D Molecular Therapeutics's next earnings date?
Unfortunately, 4D Molecular Therapeutics's (FDMT) next earnings date is currently unknown.
-
Does 4D Molecular Therapeutics pay dividends?
No, 4D Molecular Therapeutics does not pay dividends.
-
How much money does 4D Molecular Therapeutics make?
4D Molecular Therapeutics has a market capitalization of 272.05M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 562.29% to 20.72M US dollars.
-
What is 4D Molecular Therapeutics's stock symbol?
4D Molecular Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "FDMT".
-
What is 4D Molecular Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of 4D Molecular Therapeutics?
Shares of 4D Molecular Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are 4D Molecular Therapeutics's key executives?
4D Molecular Therapeutics's management team includes the following people:
- Dr. David H. Kirn Co-Founder, Chief Executive Officer, Pres & Director(age: 62, pay: $701,530)
- Mr. August J. Moretti Esq., J.D. Chief Financial Officer(age: 74, pay: $632,760)
- Dr. Robert S. Fishman Chief Medical Officer & Therapeutic Area Head of Pulmonology(age: 63, pay: $184,620)
- Dr. David E. Schaffer Ph.D. Co-Founder, Chief Scientific Advisor & Independent Director(age: 55, pay: $108,380)
- Dr. John F. Milligan Executive Chairman(age: 64, pay: $55,840)
-
Is 4D Molecular Therapeutics founder-led company?
Yes, 4D Molecular Therapeutics is a company led by its founders Dr. David H. Kirn and Dr. David E. Schaffer Ph.D..
-
How many employees does 4D Molecular Therapeutics have?
As Jul 2024, 4D Molecular Therapeutics employs 171 workers, which is 16% more then previous quarter.
-
When 4D Molecular Therapeutics went public?
4D Molecular Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 11 Dec 2020.
-
What is 4D Molecular Therapeutics's official website?
The official website for 4D Molecular Therapeutics is 4dmoleculartherapeutics.com.
-
Where are 4D Molecular Therapeutics's headquarters?
4D Molecular Therapeutics is headquartered at 5858 Horton Street, EmeryVille, CA.
-
How can i contact 4D Molecular Therapeutics?
4D Molecular Therapeutics's mailing address is 5858 Horton Street, EmeryVille, CA and company can be reached via phone at +51 05052680.
4D Molecular Therapeutics company profile:

4D Molecular Therapeutics, Inc.
4dmoleculartherapeutics.comNASDAQ
147
Biotechnology
Healthcare
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
EmeryVille, CA 94608
CIK: 0001650648
ISIN: US35104E1001
CUSIP: 35104E100